pharmacokinetics in practice and intro to pharmacogenomics Flashcards

1
Q

what is Cmax and Tmax

A

Cmax= maximum plasma concentration

tmax= time taken to reach Cmax

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is clearance?

A

Clearance (CL) = removal of drug by all eliminating organs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

whats a modified release drug

A

one that requires less frequent dosing because its effects last a lot longer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is the half life of a drug dependant on

A

Dependent on clearance (CL) of drug from body by all eliminating organs (hepatic, renal, faeces, breath)
Dependent of volume of distribution (Vd) - A drug with large Vd will be cleared more slowly than a drug with a small Vd
t1/2 is not dependent on drug dose or drug formulation
A drug will be 97% cleared from the body after 5 x half lives (considered ‘cleared’ in clinical practice)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

why is it relevant to understand drug half lives when prescribing

A

Drug dosing (short t1/2 will need more frequent dosing)
Organ dysfunction (t1/2 may be increased)
Adverse drug reactions or management of toxicity (how long will drug take to be removed and symptoms to resolve)
Short t1/2 increases risk of discontinuation/withdrawal symptoms (such drugs may need dose weaning on cessation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

at what point do we consider a drug to be clinically cleared from the body?

A

after 5X the half life of the drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

outline characteristics of STAT doses

A

Single or STAT doses: useful in treating acute conditions
Effects will usually wear off after a few minutes - hours
Most drugs require repeated dosing for a more prolonged therapeutic effect
Continuous IV infusion
Repeat IV dosing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

define steady state, Css and time to Css

A

Steady state = rate of drug input is equal to rate of drug elimination
Css = drug plasma concentration at steady state
Time to Css = 5 x t1/2 (after treatment initiation and after a dose increase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what effects on Css and time to Css would continuous IV infusion have

A

50% dose reduction leads to 50% reduction in Css
Time to Css is unchanged (as the t1/2 remains the same)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is the therapeutic window?

A

Aim for Css which lies between the Maximum safe concentration (MSC) and minimum effective concentration (MEC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the difference between first-order kinetics and zero-order kinetics

A

first order kinetics:Definition: The rate of drug elimination is proportional to the concentration of the drug in the plasma.

Zero-Order Kinetics:
Definition: The rate of drug elimination is constant and independent of the plasma drug concentration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

give some examples of when continuous IV infusion would be used.

A

Critical care patients
Antibiotics
Unfractionated heparin
General anaesthetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

how do the Cmax and Tmax differ between single oral dose and single modified release oral dose

A
  • modified has a lower Cmax because there is less absorption from the GI tract
  • increased Tmax because of this slower absorption
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is T12

A
  • the time taken for plasma drug conc to fall to 50%
  • used mainly in IV administer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

define pharmacogenomics.

A

‘The use of genetic and genomic information to tailor pharmaceutical treatment to an individual.’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

how do genomic variations cause pharmacodynamics?

A

variations in drug receptor
variations in efficacy (‘on’ targets)
increased incidence of adverse drug reactions (ADRs) (‘on’ and ‘off’ targets)

17
Q

how do genomic variations cause pharmacokinetics?

A

variations in drug metabolism (eg CYP450 enzymes)
variations in efficacy
increased incidence in adverse drug reactions

18
Q

what are the different routes that drugs can be excreted?

A

Renal (Kidneys):
Through urine via glomerular filtration, tubular secretion, and tubular reabsorption.

Hepatic (Bile and Feces):
Excreted into bile or directly into feces.
May undergo enterohepatic recycling.

Pulmonary (Lungs):
Exhalation of gaseous or volatile substances.

Sweat:
Excreted through sweat glands.

Saliva:
Diffusion into salivary secretions.

Breast Milk:
Secretion during lactation.

Other Minor Routes:
Tears.
Hair.
Skin.

19
Q

describe the graph of single dose IV administration

A

Key Characteristics:
Immediate peak concentration: Drug enters directly into the bloodstream, bypassing the absorption phase.
No lag time: Rapid onset of action as the drug is immediately available for distribution.
Exponential decline: The plasma concentration decreases over time due to distribution to tissues and elimination (metabolism and excretion).
Phases:
Distribution Phase: Initially, the drug rapidly moves from the bloodstream to tissues.
Elimination Phase: A slower decline in plasma concentration as the drug is metabolized and excreted.
Graph Shape:
A sharp spike at the time of administration, followed by a biexponential or monoexponential decline depending on the drug’s pharmacokinetics.

20
Q

describe the graph of a single dose oral administered drug and name factors which effect this.

A

Lag phase: A delay before the drug appears in the plasma due to absorption from the gastrointestinal tract.
Gradual rise to peak concentration: The rate of drug absorption exceeds the rate of elimination during this phase.
Peak plasma concentration (C
m
a
x
max

): Reached when absorption rate equals elimination rate.
Decline phase: Plasma concentration decreases as elimination exceeds absorption.

Factors Influencing the Curve:
Absorption rate: Slower absorption results in a delayed and lower C
m
a
x
max

.
Bioavailability: The fraction of the oral dose that reaches systemic circulation affects the overall plasma concentration.
First-pass metabolism: Oral drugs may undergo significant metabolism in the liver before reaching the bloodstream, reducing plasma levels.
Graph Shape:
An ascending curve leading to C
m
a
x
max

, followed by a descending curve as elimination predominates.

21
Q

compare the difference in graphs with single oral dose and modified release dose.

A

Key Characteristics:
Slower absorption phase: Drug release is controlled over an extended period, leading to gradual absorption into the bloodstream.
Reduced peak concentration: The peak plasma concentration is lower than with a single oral dose, minimizing the risk of toxicity.
Prolonged therapeutic effect: Maintains plasma levels within the therapeutic window for a longer duration, reducing the need for frequent dosing.
Smoother curve: Avoids the “peaks and troughs” associated with single oral dosing.
Graph Features:
A gradual rise in plasma concentration with a lower Cmax
​-increased Tmax
.
A plateau-like phase where plasma concentration is maintained within the therapeutic range for an extended period.
A slower decline as the drug is released and eliminated gradually.

22
Q

outline the characteristics of a single IV dose

A

Key Characteristics:
Immediate peak concentration: Drug enters the bloodstream directly, achieving 100% bioavailability instantly.
No absorption phase: Bypasses the gastrointestinal tract and first-pass metabolism.
Rapid decline: Plasma concentration decreases exponentially due to distribution into tissues and elimination.
Short duration of action: Drug levels quickly fall below the therapeutic range, requiring frequent dosing for sustained effects.
Graph Features:
Instantaneous spike in plasma concentration (C
m
a
x
max

).
Rapid, exponential decline due to distribution and elimination.
No lag or absorption phase.

23
Q

contrast single IV dose 100% with single IV dose 50%

A

Half the normal dose administered intravenously. The drug enters the bloodstream immediately, but only 50% of the intended dose is delivered.
Lower peak concentration (C
m
a
x
max

): Because only 50% of the drug is administered, the plasma concentration will reach half the level compared to the full-dose IV administration.
Similar distribution and elimination: While the amount in circulation is lower, the distribution and elimination follow the same pattern as the full dose.
Shorter duration of action: With less drug in the system, plasma levels will decline more rapidly.
Graph Features:
Lower initial concentration due to half the dose being administered.
Exponential decline similar to the full-dose graph but starting from a lower peak.
- 50% Css reduction
- time to Css is the same

24
Q

contrast continuous IV infusion and reduced clearance continuous IV infusion

A

Continuous IV Infusion (Standard Clearance):
Gradual increase in plasma concentration over time, reaching steady-state after several half-lives.
Plasma levels remain at a normal steady-state concentration.
After stopping the infusion, plasma concentration declines exponentially based on normal clearance.
Reduced Clearance Continuous IV Infusion:
Slower rise to steady-state due to slower drug elimination.
Reaches a higher steady-state concentration.
After stopping the infusion, the plasma concentration declines more slowly due to the reduced clearance rate.
- reduced cl - increased time to cl
- time to css inc
- css inc
- dose reduction required

25
Q

what can be used to reduce the time to steady state and why would we want to do this?

A

Waiting to reach steady state may be detrimental
A loading dose will speed up time to steady state

26
Q

outline some key points about loading dose

A

Purpose: To reach the therapeutic plasma concentration quickly.
Administration: Often much larger than the regular maintenance dose.
Time to Reach Steady State: Reduces the time it takes for the drug to reach therapeutic levels, especially when the drug has a long elimination half-life.
Maintenance Dosing: After the loading dose, smaller, regular doses are given to maintain steady-state levels.

27
Q

Outline how pharmacogenomics can support safe and effective prescribing, for example with opioid use.

A
  • variations in CYP enzymes effect metabolizers
  • can be used to see peoples levels of metabolism so we can alter dosage
  • if it means unsafe or ineffective administration, can administer different drug
  • reduce side effects
  • reduce dependancy